Top Markets
Coin of the day
Aerovate Therapeutics, Inc. Aerovate Therapeutics, Inc.

Aerovate Therapeutics, Inc.

AVTE
Rangering i aksjer #5459
Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise... Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise focused on innovating therapies to enhance the well-being of patients afflicted with rare cardiopulmonary illnesses across the United States. The company's principal effort involves advancing AV-101, an inhaled dry powder variant of imatinib, which is currently undergoing a Phase 2b/Phase 3 clinical study for the management of pulmonary arterial hypertension. Established in 2018, Aerovate Therapeutics, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Aksjekurs
$93.80
Sist synkronisert: 2025-04-28
Markedsverdi
$2.68B
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Aerovate Therapeutics, Inc. (AVTE)

Kategori

P/B-forhold for Aerovate Therapeutics, Inc. (AVTE)
P/B-forhold per August 2026 TTM: 0.37
Ifølge Aerovate Therapeutics, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0.37. Ved slutten av 2023 hadde selskapet et P/B-forhold på 5.44.
P/B-historikk for Aerovate Therapeutics, Inc. fra 2020 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
2026 (TTM) 0.37 -100.02%
2024 -1.62K -29,830.16%
2023 5.44 -3.77%
2022 5.66 238.93%
2021 1.67 -99.12%
2020 189.49 0.00%
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
6.3419 1,605.27%
US
6.2413 1,578.22%
NL
3.7087 897.23%
US
2.5054 573.68%
AU
- -
CH